NSEChange in Director(s)5d ago · 17 Jul 2026, 03:48 pm
Change in Director(s)
Tatva Chintan Pharma Chem Limited · TATVA
✦ AI SummaryMgmt Change
Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Change in Director(s) of the company, including the re-appointment of three directors and the approval of a proposed capacity expansion and increase in borrowing limits.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Change in Director(s) of the company.
Attachments (1)
📄pdf
Download →
TATVA_17072026154752_O.pdf
View document text
Date: 17 July 2026 Ref. No.: TCPCL/SEC/2026-27/00021
The General Manager, The Manager,
Corporate relationship department, Listing department,
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G,
Dalal Street, Fort, Bandra-Kurla Complex, Bandra(E),
Mumbai-400 001 Mumbai-400 051
Scrip Code: 543321 Scrip Symbol: TATVA
Subject: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended
Dear Sir/Madam,
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (the "SEBI Listing Regulations"), we wish to inform you that the Board of Directors
of Tatva Chintan Pharma Chem Limited (the "Company") at its meeting held today i.e. 17 July 2026
have inter-alia, approved and taken on record the following items:
1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended
30 June 2026. In this regard, please find enclosed:
i. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter
ended 30 June 2026; and
ii. Limited Review Report (Standalone and Consolidated) for the quarter ended 30 June 2026,
issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W),
Statutory Auditors of the Company.
2. The Board, based on the recommendation of Nomination and Remuneration Committee, has
approved the re-appointment of Mr. Chintan Nitinkumar Shah (DIN: 00183618) designated as
Managing Director of the Company, liable to retire by rotation, for a further period of three (3)
years from 01 February 2027 to 31 January 2030 (both days inclusive), subject to approval of the
Members at the ensuing Annual General Meeting of the Company.
3. The Board, based on the recommendation of Nomination and Remuneration Committee, has
approved the re-appointment of Mr. Ajaykumar Mansukhlal Patel (DIN: 00183745) designated as
Whole-time Director of the Company, liable to retire by rotation, for a further period of three (3)
years from 01 February 2027 to 31 January 2030 (both days inclusive), subject to approval of the
Members at the ensuing Annual General Meeting of the Company.
4. The Board, based on the recommendation of Nomination and Remuneration Committee, has
approved the re-appointment of Mr. Shekhar Rasiklal Somani (DIN: 00183665) designated as
Whole-time Director of the Company, liable to retire by rotation, for a further period of three (3)
years from 01 February 2027 to 31 January 2030 (both days inclusive), subject to approval of the
Members at the ensuing Annual General Meeting of the Company.
5. The Board has approved the proposed capacity expansion (addition) of manufacturing capacities
of various specialty chemicals at the new greenfield unit at Dahej - III, Dahej Industrial Estate,
Taluka: Vagra, District: Bharuch, Gujarat, India. As part of our growth strategy, the new
manufacturing facility (unit) will further strengthen the Company’s infrastructure and help to
meet growing market demands.
6. The Board has approved the proposal for increase in the borrowing limits of the Company
pursuant to Section 180(1)(c) of the Companies Act, 2013, from Rs. 300,00,00,000 (Rupees Three
Hundred Crores only) to Rs. 1,000,00,00,000 (Rupees One Thousand Crores only), subject to
approval of the Members at the ensuing Annual General Meeting of the Company.
Disclosure under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No.
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on 11 July 2023 and last updated on 30 January
2026 for the matters mentioned at Item 2, 3, 4, and 5 above, is enclosed herewith as “Annexure A”.
The above information shall be made available on the website of the Company at
www.tatvachintan.com.
The Meeting commenced at 11:30 A.M. and concluded at 03:40 P.M.
Kindly take above intimation on your record and oblige.
Thanking you,
Yours faithfully,
For Tatva Chintan Pharma Chem Limited
Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444
Encl.: As above
Disclosure under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No.
HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on 11 July 2023 and last updated on 30 January 2026.
Annexure A
Sr. Particulars Mr. Chintan Nitinkumar Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal
No. Shah Patel Somani
(Managing Director) (Whole-time Director) (Whole-time Director)
1. Reason for change Re-appointment of Mr. Chintan Re-appointment of Mr. Re-appointment of Mr.
viz. appointment, Nitinkumar Shah (DIN: Ajaykumar Mansukhlal Patel Shekhar Rasiklal Somani
re-appointment, 00183618) as Managing Director (DIN: 00183745) as (DIN: 00183665) as
resignation, removal, of the Company Whole-time Director of the Whole-time Director of the
death or otherwise Company Company
2. Date of appointment / Date of re-appointment: 01 Date of re-appointment: 01 Date of re-appointment: 01
re-appointment / February 2027 February 2027 February 2027
cessation (as
applicable) & term of Re-appointment for a further Re-appointment for a further Re-appointment for a further
appointment / period of three (3) years from 01 period of three (3) years from 01 period of three (3) years from
re-appointment February 2027 to 31 January 2030 February 2027 to 31 January 2030 01 February 2027 to 31 January
(both days inclusive), subject to (both days inclusive), subject to 2030 (both days inclusive),
the approval of the members of the approval of the members of subject to the approval of the
the Company the Company members of the Company
His present tenure as Managing His present tenure as Whole-time His present tenure as
Director will conclude on 31 Director will conclude on 31 Whole-time Director will
January 2027 January 2027 conclude on 31 January 2027
3. Brief profile (in case Mr. Chintan Nitinkumar Shah, Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal Somani,
of appointment) aged 53, is a Bachelor of Patel, aged 54, is a Bachelor of aged 52, is a Bachelor’s
Engineering (Computer Engineering (Chemical). He is degree in pharmacy. He is one
Science). He is one of the one of the founding members of the founding members and
founding members and and promoters of Tatva Chintan promoters of Tatva Chintan
promoters of Tatva Chintan Pharma Chem Limited. He Pharma Chem Limited. He
Pharma Chem Limited. He joined the Company in the year joined the Company in the
joined the Company in the year 1996. He has over 31 years of year 1996. He has over 30
1996. He has over 30 years of experience in the manufacturing years of experience in the
experience in the manufacturing / specialty chemical industry. manufacturing / specialty
/ specialty chemical industry. He holds following position in chemical industry.
He holds following position in the subsidiary of the Company. He holds following position
the subsidiary of the Company. Tatva Chintan USA Inc. - in the subsidiary of the
Tatva Chintan USA Inc. - Director and Treasurer Company.
President and Director Tatva Chintan Europe B.V. - Tatva Chintan USA Inc. -
Tatva Chintan Europe B.V. - Board Member Director and Secretary
Board Member Tatva Chintan Europe B.V. -
Board Member
4. Disclosure of Mr. Chintan Nitinkumar Shah is Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal Somani
Relationship between not related to any of the Patel is not related to any of the is not related to any of the
Directors (in case of Directors of the Company Directors of the Company Directors of the Company
appointment as a
Director)
5. Information as Mr. Chintan Nitinkumar Shah is Mr. Ajaykumar Mansukhlal Mr. Shekhar Rasiklal Somani
required pursuant to not debarred from holding the Patel is not debarred from is not debarred from holding
BSE Circular with ref. office of Director by virtue of holding the office of Director the office of Director by
no. any SEBI Order or any other by virtue of any SEBI Order or virtue of any SEBI Order or
LIST/COMP/14/2018 such Authority
[Showing first 8,000 characters — download PDF for full document]